Home › Funds › Nicholas Investment Partners, LP › RYTM
Nicholas Investment Partners, LP position in RYTM
RHYTHM PHARMACEUTICALS INC · Health Care
Nicholas Investment Partners, LP reported holding 117,413 shares of RYTM (RHYTHM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$11.2M, representing 0.84% of its reported portfolio and ranking #37 among its reported holdings. Nicholas Investment Partners, LP has disclosed RYTM holdings in 3 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Nicholas Investment Partners, LP's RYTM position evolved
Nicholas Investment Partners, LP first disclosed a stake in RYTM in Q4 2025 at 34,710 shares (US$3.7M). The position peaked in Q2 2026 at 139,270 shares, worth US$15.5M. Across 3 filings, Nicholas Investment Partners, LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 117,413 shares valued at US$11.2M — a reduction of -21,857 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 34.71K | $3.72M | New |
| Q2 2026 | 139.27K | $15.46M | New |
| Q3 2026 | 117.41K | $11.18M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RYTM and 13F data
RYTM (RHYTHM PHARMACEUTICALS INC) is a Health Care company. 40 other funds we track also report a position in RYTM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$740.2M), BAKER BROS. ADVISORS LP (US$622.3M), PERCEPTIVE ADVISORS LLC (US$287.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RYTM
- RA CAPITAL MANAGEMENT, L.P. 6.67M sh · $740.22M · Q2 2026
- BAKER BROS. ADVISORS LP 5.60M sh · $622.27M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.59M sh · $287.16M · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 2.48M sh · $236.20M · Q3 2026
- Checkpoint Capital L.P. 1.22M sh · $115.84M · Q3 2026
- Siren, L.L.C. 1.09M sh · $103.43M · Q3 2026
- Rock Springs Capital Management LP 692.60K sh · $65.95M · Q3 2026
- Sofinnova Investments, Inc. 534.54K sh · $50.90M · Q3 2026
More on Nicholas Investment Partners, LP
FAQ
How long has Nicholas Investment Partners, LP held RYTM?
Nicholas Investment Partners, LP has disclosed RYTM holdings in 3 of the last 4 reported quarters, going back to Q4 2025.
What is Nicholas Investment Partners, LP's current position in RYTM?
As of Q3 2026, Nicholas Investment Partners, LP holds 117.41K shares of RYTM (RHYTHM PHARMACEUTICALS INC), valued at $11.18M, representing 0.84% of its reported portfolio and ranking #37.
Has Nicholas Investment Partners, LP been buying or selling RYTM?
In the latest 13F filing (Q3 2026), Nicholas Investment Partners, LP reduced its position in RYTM. The position peaked in Q2 2026 at 139.27K shares.
Which other funds hold RYTM?
Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., BAKER BROS. ADVISORS LP, PERCEPTIVE ADVISORS LLC, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.